KB-1185

Enfortumab

Background

Nectin-4 is a type I membrane protein. The extracellular region of Nectin-4 dimer consists of three Ig domains, Ig V type and IgC type. Nectin-4 is overexpressed in a variety of tumor cells and can promote the growth and proliferation of tumor cells. Enfortumab vedotin a "first-in-class" drug developed by Astellas and Seagen, is an ADC drug that combines enfortumab targeting Nectin-4 with the microtubule destroyer MMAE via a cleavable dipeptide linker. Enfortumab vedotin binds to Nectin-4 on the surface of tumor cells and enters the tumor cells through endocytotic action. After the dipeptide linker is cleaved by proteolytic enzymes in the cell, the toxin MMAE can be released and targeted to kill the tumor.

Specifications

Catalog Number:
KB-1185
Cell Line Name:
Enfortumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
Nectin-4
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Evan Y Yu;Daniel P Petrylak;Peter H O'Donnell;Jae-Lyun Lee;Michiel S van der Heijden;Yohann Loriot;Mark N Stein;Andrea Necchi;Takahiro Kojima;Michael R Harrison;Se Hoon Park;David I Quinn;Elisabeth I Heath;Jonathan E Rosenberg;Joyce Steinberg;Shang-Ying Liang;Janet Trowbridge;Mary Campbell;Bradley McGregor;Arjun V Balar; (2021). Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV_x005F 201): a multicentre, single-arm, phase 2 trial . The Lancet Oncology.  2.Jens Bedke;Moritz Maas; (2021). Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma . European Urology.  3.Challita-Eid, P. M.; Satpayev, D.; Yang, P.; An, Z.; Morrison, K.; Shostak, Y.; Raitano, A.; Nadell, R.; Liu, W.; Lortie, D. R.; Capo, L.; Verlinsky, A.; Leavitt, M.; Malik, F.; Avina, H.; Guevara, C. I.; Dinh, N.; Karki, S.; Anand, B.; Pereira, D. S.; Joseph, I. B. J.; Donate, F.; Morrison, K.; Stover, D. R. (2016). Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Research, 0008-5472.CAN-15-1313.
Please enable JavaScript in your browser to complete this form.